Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Gynecol Endocrinol ; 39(1): 2239936, 2023 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-37494965

RESUMO

OBJECTIVES: Some plants, such as Dioscorea Villosa (DV), Vitex Agnus Castus (VAC) and Turnera diffusa (D) have some 'progesterone-like' properties. We have investigated their simultaneous administration in breast cancer (BC) survivors or carriers of specific genetic mutations that can increase the risk of developing BC suffering from abnormal uterine bleeding without organic cause. METHODS: Women with irregular cycles in terms of length (interval between ≤ 24 or ≥ 38 days) without a uterine organic disease (polyps, adenomyosis, fibroids, hyperplasia/malignancy) were included. A daily diary of bleeding, questionnaires about health-related quality of life (Short Form 36) and menstrual psychophysical well-being (PGWB-1) and the Greene Climacteric Scale (GCS) (in women older than 40 years old) questionnaire were used. The presence of some premenstrual syndrome (PMS) symptoms was also evaluated. RESULTS: In the analyzed group of women (n = 15), all experienced a regularization of the menstrual cycles, with a mean duration in the three months of use of 27.1 ± 3.2 days, with a significant reduction of menstrual pain (p = 0.02) and flow (p = 0.02) intensity. Women with PMS (7/15) reported an impovement in depression, headache and abdominal pain scores (p < 0.05). No specific deterioration of different questionnaires evaluated during treatment were observed. General satisfaction with the treatment was 6.8 ± 0.3/10 on a 10 point. CONCLUSIONS: A combination of DV, VAC and D could be a promising candidate to treat menstrual irregularities without an organic cause, with a significant reduction of menstrual pain and flow intensity and possible additional benefits in PMS symptoms treatment in women at genetic risk for BC and BC survivors.


Assuntos
Neoplasias da Mama , Sobreviventes de Câncer , Síndrome Pré-Menstrual , Doenças Uterinas , Vitex , Feminino , Humanos , Adulto , Progestinas , Projetos Piloto , Neoplasias da Mama/complicações , Estudos Prospectivos , Dismenorreia , Qualidade de Vida , Síndrome Pré-Menstrual/tratamento farmacológico , Hemorragia Uterina
2.
Arch Gynecol Obstet ; 307(3): 873-879, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36409333

RESUMO

PURPOSE: A new POP consisting of 4 mg drospirenone (DRSP) for 24 days with a 4-day hormone-free interval was developed to improve bleeding predictability during POP use. The aim of this study was to evaluate the effect on bleeding patterns during use of this oral contraceptive (OC) in comparison with previous menstrual cycles before the start of OC use. METHODS: This is a pilot, prospective trial. A diary was used to collect information about daily bleeding and pelvic pain before and during treatment. During OC use, women were categorised as having (1) unscheduled bleeding or spotting days (UB), (2) scheduled bleeding or spotting days (SB) and (3) absence of bleeding/spotting (AB). SF-36 and FSFI questionnaires were used to quantify health-related quality of life and the quality of sexual life in sexually active participants. RESULTS: Eighteen out of twenty-five (72%) women completed the entire follow-up. Women with UB (44.4%) were older at inclusion (p < 0.001) and had higher BMIs (p = 0.02) than those with AB (22.2%) or SB (33.4%). Women recorded a significant reduction of menstrual flow intensity during OC use (p < 0.0001). Those with UB also experienced a significant reduction of menstrual pain intensity (p = 0.006). Women with SB during OC use had a longer baseline cycle than those who reported UB during OC use (p = 0.008). Satisfaction with this OC was very high (8.4 ± 2.2 points) with no modification in SF-36 and FSFI values. CONCLUSION: A DRSP-only pill is a good OC option for women with contraindications to oestrogen use. Features of the menstrual cycle before the start of OC use may be used to predict associated changes in bleeding patterns.


Assuntos
Anticoncepcionais Orais , Qualidade de Vida , Feminino , Humanos , Masculino , Anticoncepção , Anticoncepcionais Orais Combinados , Contraindicações , Estrogênios , Etinilestradiol , Ciclo Menstrual , Estudos Prospectivos , Projetos Piloto
3.
Gynecol Endocrinol ; 38(1): 63-67, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34658291

RESUMO

OBJECTIVE: The beneficial effects of Vitamin D (VD) and Epigallocatechin gallate (EGCG), a polyphenol of green tea, on the growth of uterine fibroids (UF) were previously described in vitro and in vivo. We have decided to investigate their simultaneous administration in women with UFs in late reproductive life. METHODS: >40 years old n = 16 premenopausal women with intramural (IM) or subserosal (SS) UF of ≥3 cm or several UFs of different sizes, even smaller but with a total diameter ≥3 cm but <10 cm, without further concomitant organic causes of abnormal uterine bleeding, treated with EGCG 300 mg, Vitamin B6 10 mg and VD 50 µg/day for 90 days. Women completed a diary on a daily basis to obtain information about bleeding and pelvic pain. RESULTS: We have observed a significant reduction in UF's mean size both at patient's (-17.8%, p = .03) and at single UF's level (-37.3%, p = .015). The effect was more evident in women with predominant IM (p = .016) in comparison to SS UFs. No significant changes were observed for uterine and ovarian volume and endometrial thickness during treatment. We reported a significant decrease in menstrual flow length of 0.9 day (p = .04) with no modification in cycle length, menstrual flow intensity and menstrual pain intensity. The satisfaction with treatment was in general very high, with no adverse effects reported. CONCLUSION: The concomitant administration of VD and EGCG represents a promising treatment of UF in women of late reproductive life for which hormonal manipulation is not foreseen.


Assuntos
Leiomioma/tratamento farmacológico , Projetos Piloto , Extratos Vegetais/uso terapêutico , Chá/química , Neoplasias Uterinas/tratamento farmacológico , Vitamina D/uso terapêutico , Adulto , Catequina/administração & dosagem , Catequina/análogos & derivados , Feminino , Humanos , Pré-Menopausa , Estudos Prospectivos
4.
Eur J Contracept Reprod Health Care ; 27(6): 439-444, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-35946412

RESUMO

OBJECTIVE: To evaluate the actual perceptions about combined hormonal contraceptives (CHCs) use in BRCA mutation carriers in comparison to women from the general population. METHODS: This was a cross-sectional, observational study involving two Italian referral centres for hereditary cancers. An identical questionnaire investigating how CHC use could affect the risk of developing some types of cancer, specific diseases, and symptoms was administered to 85 BRCA mutation carriers and 85 healthy women without this genetic mutation (control group). Women's perceptions were evaluated using specific questions and Likert scales (-5 to +5). RESULTS: Perceptions about the effects of CHC use on developing specific diseases and symptoms did not differ between BRCA mutation carriers and controls. Conversely, the protective effects of CHC use on colorectal (p = .02), uterine body (p = .01) and ovarian (p = .01) cancers were unknown by BRCA mutation carriers. Moreover, BRCA mutation carriers recognised the association between CHC use and a higher risk of breast (p = .0008) and uterine cervix cancer (p = .007). CONCLUSIONS: Investing time and effort in transmitting the correct key messages about oncological risk related to CHC use could potentially increase their use in BRCA mutation carriers.


Assuntos
Anticoncepcionais , Conhecimentos, Atitudes e Prática em Saúde , Percepção , Feminino , Humanos , Estudos Transversais , Mutação , Medição de Risco , Heterozigoto , Genes BRCA1 , Genes BRCA2
5.
Minerva Obstet Gynecol ; 76(3): 250-256, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38939979

RESUMO

BACKGROUND: Pelvic congestion syndrome (PCS) is associated with chronic pelvic pain (CPP). The efficacy of flavonoids for treating PCS symptoms is still a matter of debate, and little has been published. The aim of this study was to assess the efficacy of a mixture of diosmin, troxerutin, and hesperidin in improving symptoms of patients with PCS, observing a direct effect on circulation by specific color Doppler ultrasonography (CDU) evaluations. METHODS: This was a pilot, prospective, independent, cross-over, daily-diary-based trial. Women were evaluated with CDU for 3 times (baseline, 60 days, 120 days). Data about N.=13 women who completed the study were analyzed. RESULTS: During the treatment, we recorded a significant reduction of intermenstrual and menstrual pain intensity (total points) (P<0.05). The satisfaction after treatment was significantly higher than after placebo (P<0.0001). A significant reduction in the diameter of the major ovarian vein (P=0.004 compared to placebo), associated with an increase in peak systolic velocity (P=0.01) and a corresponding significant increase in the Resistivity Index (P<0.0001) were recorded during treatment. CONCLUSIONS: The use of a mixture of diosmin, troxerutin and hesperidin in women with PCS can significantly help to manage typical symptoms of pelvic pain and it is associated with an evident Doppler effect on pelvic microcirculation.


Assuntos
Estudos Cross-Over , Diosmina , Hesperidina , Hidroxietilrutosídeo , Dor Pélvica , Ultrassonografia Doppler em Cores , Humanos , Feminino , Hidroxietilrutosídeo/análogos & derivados , Hidroxietilrutosídeo/uso terapêutico , Hidroxietilrutosídeo/farmacologia , Diosmina/uso terapêutico , Diosmina/farmacologia , Diosmina/administração & dosagem , Hesperidina/uso terapêutico , Dor Pélvica/tratamento farmacológico , Dor Pélvica/diagnóstico por imagem , Dor Pélvica/etiologia , Adulto , Estudos Prospectivos , Projetos Piloto , Síndrome , Adulto Jovem , Resultado do Tratamento , Ovário/efeitos dos fármacos , Ovário/diagnóstico por imagem , Ovário/irrigação sanguínea , Combinação de Medicamentos
6.
Ann Med ; 53(1): 908-915, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34124968

RESUMO

INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were evaluated using specific questions and Likert scales (-5 to +5).Multivariate regression analyses were adjusted for categories of HC/HT use (never, past and current). RESULTS: The most reported adverse effect associated with hormonal treatments was venous thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women (p < .0001). According to responses, hormonal treatments can increase the risk of developing venous thrombosis (OR 0.79; 95% CI 0.67-0.96, p = .004) and depression (OR 0.80; 95% CI 0.69-0.92, p = .002) more in pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR 1.24: 95% CI 1.07-1.42, p = .003).The greatest oncological concern throughout life was about breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19-1.75, p = .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR 0.74; 95% CI 0.52-0.97, p = .03). CONCLUSIONS: Our data suggest that our patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk.KEY MESSAGESYoung patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk.Older patients are primarily concerned about the effects of hormonal treatments on weight gain, breast and ovarian cancer risk.The greatest oncological concern throughout life was about breast cancer.


Assuntos
Neoplasias da Mama , Contraceptivos Hormonais , Anticoncepcionais , Neoplasias Ovarianas , Neoplasias do Colo do Útero , Trombose Venosa , Atitude , Neoplasias da Mama/induzido quimicamente , Neoplasias da Mama/epidemiologia , Feminino , Hormônios , Humanos , Pós-Menopausa , Fatores de Risco , Aumento de Peso
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA